Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Advanced
Wish Lists Wish Lists
Wish Lists Wish Lists
Wish Lists
Cart Cart
Cart Cart
Cart
Sign in
Sign in
Contact us
Advanced
Homepage > Company > Media > Pharma News > 2019

Pharma News, 2019

ISRACANN Biosciences: Invest in Israel’s First Cannabis Pure-Play Public Offering
ISRACANN Biosciences: Invest in Israel’s First Cannabis Pure-Play Public Offering
Seattle, Washington, April 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North Ame...
Drugmakers pay $123 million to resolve US charity kickback probe
Drugmakers pay $123 million to resolve US charity kickback probe
Three drugmakers will pay $122.
World Health Day History
World Health Day History
World Health Day seeks to draw attention to a major global health concern each year.
FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin
FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin
RAMSEY, N.
Hospital viruses: Fake cancerous nodes in CT scans, created by malware, trick radiologists
Hospital viruses: Fake cancerous nodes in CT scans, created by malware, trick radiologists
When Hillary Clinton stumbled and coughed through public appearances during her 2016 presidential run, she faced critics who said that she might not be well enough to perform the top job in the countr...
Roche's ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial
Roche's ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial
Basel, 01 April 2019 - Roche (SIX.
Adding savolitinib to osimertinib beneficial for certain pretreated lung cancer patients
Adding savolitinib to osimertinib beneficial for certain pretreated lung cancer patients
ATLANTA -- Adding the investigational MET inhibitor savolitinib to the EGFR inhibitor osimertinib (Tagrisso) yielded clinical responses in patients who had EGFR-mutant non-small cell lung canc...
Chinese scientists find a new target for gene therapy for osteoarthritis
Chinese scientists find a new target for gene therapy for osteoarthritis
BEIJING, April 2 (Xinhua) -- Chinese scientists have found a new therapeutic target for rejuvenating aging cells, shedding light on possible gene therapy for osteoarthritis.
Apexigen Announces New Clinical Data On APX005M In Combination Therapy For Pancreatic Cancer At The AACR Annual Meeting 2019
Apexigen Announces New Clinical Data On APX005M In Combination Therapy For Pancreatic Cancer At The AACR Annual Meeting 2019
SAN CARLOS, Calif.
Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy
Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy
TOKYO, April 1, 2019 /PRNewswire/ -- Astellas Pharma Inc.
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe
LOS ANGELES & CASTRES, France--(BUSINESS WIRE)--Puma Biotechnology, Inc.
FDA warns homeopathic firms for putting patients at risk with significant violations of manufacturing quality standards
FDA warns homeopathic firms for putting patients at risk with significant violations of manufacturing quality standards
The U.
0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Screening Compounds
Building blocks
Inhibitors and approved drugs
Drug Discovery Services
Custom chemistry. Chemistry FTE. Resynthesis.
Hit Follow up Support
Medicinal chemistry FTE
In silico drug design (CADD)
Discovery Biology. Biology FTE. In vitro studies.
Animal models
Toxicology and safety
ADME, DMPK. In vivo studies
Chemistry, manufacturing and controls
Company
News & Media
Contact us
Trends in discovery compounds